1,202 reports of this reaction
2.2% of all DASATINIB reports
#12 most reported adverse reaction
HOSPITALISATION is the #12 most commonly reported adverse reaction for DASATINIB, manufactured by E.R. Squibb & Sons, L.L.C.. There are 1,202 FDA adverse event reports linking DASATINIB to HOSPITALISATION. This represents approximately 2.2% of all 55,495 adverse event reports for this drug.
Patients taking DASATINIB who experience hospitalisation should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HOSPITALISATION is a less commonly reported adverse event for DASATINIB, but still significant enough to appear in the safety profile.
In addition to hospitalisation, the following adverse reactions have been reported for DASATINIB:
The following drugs have also been linked to hospitalisation in FDA adverse event reports:
HOSPITALISATION has been reported as an adverse event in 1,202 FDA reports for DASATINIB. This does not prove causation, but indicates an association observed in post-market surveillance data.
HOSPITALISATION accounts for approximately 2.2% of all adverse event reports for DASATINIB, making it a notable side effect.
If you experience hospitalisation while taking DASATINIB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.